This is a preview of subscription content, log in via an institution to check access.
Reference
Bocquet F, et al. Biosimilar Versus Patented Erythropoietins: Learning from 5 Years of European and Japanese Experience. Applied Health Economics and Health Policy : 5 Sep 2014. Available from: URL: http://doi.org/10.1007/s40258-014-0125-6
Rights and permissions
About this article
Cite this article
Uptake of biosimilar erythropoietin "highly country-specific". PharmacoEcon Outcomes News 712, 32 (2014). https://doi.org/10.1007/s40274-014-1577-5
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-014-1577-5